Robert E. Waltermire Madrigal Pharmaceuticals, Inc. (MDGL) insider trading activity

MDGL Quotes by TradingView

Robert E. Waltermire is Senior VP, Chief Pharma Dev. of MADRIGAL PHARMACEUTICALS, INC.. Currently has a direct ownership of 4,955 shares of MDGL, which is worth approximately $1.66 Million. The most recent transaction as insider was on Jan 24, 2025, when has been sold 103 shares (Common Stock) at a price of $335.24 per share, resulting in proceeds of $34,529. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 4.96K
9.91% 3M change
24.19% 12M change
Total Value Held $1.66 Million

Robert E. Waltermire Transaction History

Date Transaction Value Shares Traded Shares Held Form
Jan 24 2025
SELL
Open market or private sale
$34,529 $335.24 p/Share
103 Reduced 2.04%
4,955 Common Stock
Jan 17 2025
SELL
Open market or private sale
$120,847 $273.41 p/Share
442 Reduced 8.04%
5,058 Common Stock
Jun 14 2024
SELL
Open market or private sale
$532,000 $280.0 p/Share
1,900 Reduced 25.68%
5,500 Common Stock
Jun 14 2024
BUY
Exercise of conversion of derivative security
$165,471 $87.09 p/Share
1,900 Added 20.43%
7,400 Common Stock
Jun 12 2024
SELL
Open market or private sale
$570,000 $285.0 p/Share
2,000 Reduced 26.67%
5,500 Common Stock
Jun 12 2024
BUY
Exercise of conversion of derivative security
$175,840 $87.92 p/Share
2,000 Added 21.05%
7,500 Common Stock
May 21 2024
SELL
Open market or private sale
$239,668 $231.34 p/Share
1,036 Reduced 15.85%
5,500 Common Stock
Jan 23 2024
BUY
Grant, award, or other acquisition
-
1,419 Added 17.84%
6,536 Common Stock
Jan 16 2024
SELL
Payment of exercise price or tax liability
$134,156 $243.92 p/Share
550 Reduced 9.71%
5,117 Common Stock
Dec 15 2023
SELL
Open market or private sale
$477,000 $238.5 p/Share
2,000 Reduced 26.09%
5,667 Common Stock
Dec 15 2023
BUY
Exercise of conversion of derivative security
$175,840 $87.92 p/Share
2,000 Added 20.69%
7,667 Common Stock
Dec 14 2023
SELL
Open market or private sale
$465,000 $232.5 p/Share
2,000 Reduced 26.09%
5,667 Common Stock
Dec 14 2023
BUY
Exercise of conversion of derivative security
$175,840 $87.92 p/Share
2,000 Added 20.69%
7,667 Common Stock
Dec 13 2023
SELL
Open market or private sale
$563,750 $225.5 p/Share
2,500 Reduced 30.61%
5,667 Common Stock
Dec 13 2023
BUY
Exercise of conversion of derivative security
$219,800 $87.92 p/Share
2,500 Added 23.44%
8,167 Common Stock
Dec 12 2023
SELL
Open market or private sale
$282,750 $217.5 p/Share
1,300 Reduced 18.66%
5,667 Common Stock
Dec 12 2023
BUY
Exercise of conversion of derivative security
$114,296 $87.92 p/Share
1,300 Added 15.73%
6,967 Common Stock
Mar 01 2023
SELL
Open market or private sale
$1,374,650 $274.93 p/Share
5,000 Reduced 46.87%
5,667 Common Stock
Mar 01 2023
BUY
Exercise of conversion of derivative security
$439,600 $87.92 p/Share
5,000 Added 31.91%
10,667 Common Stock
Feb 28 2023
SELL
Open market or private sale
$1,358,300 $271.66 p/Share
5,000 Reduced 46.87%
5,667 Common Stock
Feb 28 2023
BUY
Exercise of conversion of derivative security
$439,600 $87.92 p/Share
5,000 Added 31.91%
10,667 Common Stock
Jan 16 2023
BUY
Grant, award, or other acquisition
-
5,667 Added 50.0%
5,667 Common Stock
REW

Robert E. Waltermire

Senior VP, Chief Pharma Dev.
West Conshohocken, PA

Track Institutional and Insider Activities on MDGL

Follow MADRIGAL PHARMACEUTICALS, INC. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells MDGL shares.

Notify only if

Insider Trading

Get notified when an Madrigal Pharmaceuticals, Inc. insider buys or sells MDGL shares.

Notify only if

News

Receive news related to MADRIGAL PHARMACEUTICALS, INC.

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on MDGL